Personalized Migraine Treatment and Management System

A next-generation migraine treatment system that integrates wearable devices, genetic profiling, virtual reality, machine learning, and implantable devices to provide customized and proactive migraine management.

The original patent disclosed a method for the acute treatment of migraine with or without aura using ubrogepant. However, this approach has limitations, including the need for patient self-administration, fixed dosing, and lack of real-time monitoring. The new inventive concept addresses these limitations by introducing a holistic system that combines advanced technologies to provide personalized, adaptive, and preventative migraine treatment.

The system comprises a wearable device that detects migraine onset and automatically administers a customized dose of ubrogepant based on the patient's medical history and real-time physiological data. Additionally, the system incorporates genetic profiling to tailor a ubrogepant-based treatment regimen to the patient's specific genetic predispositions. A virtual reality platform uses sensory stimulation to reduce migraine symptoms in conjunction with the ubrogepant-based treatment regimen. Machine learning algorithms predict migraine onset, enabling proactive administration of a preventative dose of ubrogepant. Furthermore, an implantable device continuously monitors and regulates CGRP levels in the patient's body, administering a customized dose of ubrogepant as needed. These components work in tandem to provide a comprehensive and adaptive migraine management system.

The new inventive concept introduces a paradigm shift in migraine treatment by integrating multiple cutting-edge technologies to provide a personalized, proactive, and adaptive system. The inventive step lies in the combination of these technologies to create a holistic system that surpasses the limitations of the original patent.

Alternative embodiments of the system could include the use of different wearable devices, such as smartwatches or skin patches, or the incorporation of other therapeutic agents in addition to ubrogepant. Variations could also include the use of artificial intelligence to analyze patient data and optimize treatment regimens.

The personalized migraine treatment and management system has significant commercial potential in the pharmaceutical and medical device industries. The system could be marketed to healthcare providers, patients, and payers, offering a comprehensive solution for migraine management. The market potential is substantial, given the high prevalence and unmet need for effective migraine treatments.